GlassScriptPhysician profile
Harsh P Patel
NPI 1750933990
$14,389.79
in general payments reported to CMS, 2019-2025
7 companies · $5,564 in 2025
The $5,564 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.96 · 2021: $33.40 · 2023: $4,761 · 2024: $4,013 · 2025: $5,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,911 · Food and Beverage: $4,028 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,910.96 |
| Food and Beverage | $4,028.37 |
| Education | $398.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,488.06 | 2024-2025 | General - Therapies, Farapulse |
| Abbott Laboratories | $4,822.09 | 2023-2025 | Gallant, Ensite, Ensite Precision |
| Medtronic, INC. | $3,798.28 | 2023-2024 | Advisa Dr Mri Surescan |
| Penumbra, INC. | $148.80 | 2024 | Indigo System |
| Sanofi-Aventis U.S. LLC | $80.20 | 2023 | |
| Linvatec Corporation | $33.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.